DiaPep 277

Summary

DiaPep 277 is a synthetic peptide derived from the heat‑shock protein 60 (Hsp60) that is being investigated as an antigen‑specific immunotherapy for type 1 diabetes. The goal is to modulate the autoimmune response that destroys pancreatic beta‑cells, potentially preserving endogenous insulin production and reducing the need for exogenous insulin.

Mechanism of Action

The peptide represents a fragment of Hsp60 that can be recognized by the immune system. By presenting this epitope, DiaPep 277 is intended to induce tolerance toward islet‑cell antigens, dampening autoreactive CD8⁺ T‑cell activity and shifting cytokine profiles away from pro‑inflammatory pathways. This antigen‑specific modulation aims to protect beta‑cells from immune‑mediated destruction.

What the Research Shows

A 2010 review listed DiaPep 277 among emerging strategies for preventing type 1 diabetes, noting its investigational status. A 2013 clinical‑immunology article described early human trials that included DiaPep 277 as an antigen‑specific therapy. The authors referred to a randomized, placebo‑controlled study in 80 adults with type 1 diabetes that reported encouraging immunologic changes, such as reduced proinsulin‑specific CD8⁺ T cells and trends toward higher C‑peptide, lower HbA1c, and reduced insulin use. However, the abstract provides no quantitative outcomes, and the discussion focuses on the broader DNA‑plasmid platform rather than definitive efficacy data for DiaPep 277 itself.

Reported Benefits

Preliminary evidence suggests that DiaPep 277 can modulate autoimmune responses in type 1 diabetes, with reported reductions in proinsulin‑specific CD8⁺ T cells and possible preservation of C‑peptide levels. Early trials indicate potential improvements in glycemic control and insulin requirements, although these findings remain exploratory and have not been confirmed in larger, definitive studies.

Limitations of the Evidence

Data on DiaPep 277 are limited to early‑phase, small‑sample trials and a narrative review; no large‑scale, phase‑III results are available. The abstracts do not provide detailed efficacy metrics, and the long‑term durability of any immunologic benefit is unknown. Consequently, the therapeutic value remains uncertain pending further rigorous clinical evaluation.

Safety Considerations

Safety information in the cited abstracts is sparse. Early investigations reported an acceptable tolerability profile, but specific adverse events, frequency, or severity were not detailed. As an investigational peptide administered subcutaneously, comprehensive safety assessments are still needed before broader clinical use can be recommended.

How It Is Administered

DiaPep 277 is administered by subcutaneous injection as a synthetic peptide formulation. The investigational protocols have explored various dosing schedules, but the exact regimen has not been standardized in the published literature.

Routes of Administration

Goals & Uses

• Reduction of exogenous insulin requirementsMetabolicLow
• Preservation of beta-cell function in type 1 diabetesAutoimmune / EndocrineModerate
• Reduce exogenous insulin requirementClinical OutcomeModerate
• Preserve C‑peptide secretionDisease ModificationModerate
• Immune tolerance inductionImmunologyLow

Contraindications

• Known hypersensitivity to DiaPep277 or any formulation componentAllergyHigh
• Immunosuppressive therapyPharmacologicalModerate
• Known hypersensitivity to peptide componentsAllergyHigh
• Active systemic infectionInfectiousModerate

Adverse Effects

• Hypersensitivity reactionsImmunologicRare
• Flu-like symptomsSystemic/ImmunologicalUncommon
• Injection site reactionsLocalCommon
• Transient flu‑like symptomsSystemicUncommon
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• Immunosuppressants (e.g., corticosteroids, azathioprine)Moderate
• Other immunomodulatory biologicsModerate
• Immunosuppressants (e.g., tacrolimus)Moderate

Population Constraints

• Long-standing type 1 diabetes with no residual beta-cell functionDisease SpecificAbsolute
• Pediatric patients (<18 years)AgeRelative
• Children <12 yearsAgeRelative
• Pregnancy and lactationReproductiveRelative

Regulatory Status

• European UnionInvestigationalClinical trial status; not authorized for marketing.
• United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
• United KingdomUnapprovedNo approval sought or granted in the UK.

Phase III trials did not meet primary endpoints; not approved in any jurisdiction and no commercial product exists.

Evidence & Sources

• Emerging treatments for the prevention of type 1 diabetes
  Journal ArticleModerateRaskin P, Mohan A2010-01-01T00:00:00.000000Z
• Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform
  Journal ArticleModerateGottlieb P, et al.2013-01-01T00:00:00.000000Z

Frequently Asked Questions